Market capitalization | $2.49m |
Enterprise Value | $-3.42m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.35 |
EV/Sales (TTM) EV/Sales | -34.20 |
P/S ratio (TTM) P/S ratio | 24.90 |
P/B ratio (TTM) P/B ratio | 0.34 |
Revenue growth (TTM) Revenue growth | -83.72% |
Revenue (TTM) Revenue | $100.00k |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Midatech Pharma Plc Sponsored ADR:
1 Analyst has issued a forecast Midatech Pharma Plc Sponsored ADR:
Jun '24 |
+/-
%
|
||
Revenue | 0.10 0.10 |
84%
84%
|
|
Gross Profit | -0.24 -0.24 |
-
|
|
EBITDA | -9.74 -9.74 |
9%
9%
|
EBIT (Operating Income) EBIT | -10 -10 |
9%
9%
|
Net Profit | -8.58 -8.58 |
12%
12%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Midatech Pharma Plc commercializes oncology treatments and cancer supportive care products through its U.S. commercial organization, Midatech Pharma US. The company engages in the development of pharmaceutical products utilizing its nanomedicine and sustained release technologies. Its pipeline includes MTD119, MTX102, MTD201 and MTX110. Midatech Pharma was founded on September 12, 2014 and is headquartered in Cardiff, the United Kingdom.
Head office | United Kingdom |
CEO | Stephen Stamp |
Employees | 21 |
Founded | 2000 |
Website | www.biodexapharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.